Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. - Wikidata - wikimedia - TriplyDB

Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices.

Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices.

http://www.wikidata.org/entity/Q47682346

about

N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study Clinical Correlates and Prognostic Value of Plasma Galectin-3 Levels in Degenerative Aortic Stenosis: A Single-Center Prospective Study of Patients Referred for Invasive Treatment Usefulness of combining galectin-3 and BIVA assessments in predicting short- and long-term events in patients admitted for acute heart failure.Gene expression changes associated with myocarditis and fibrosis in hearts of mice with chronic chagasic cardiomyopathy.Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure.Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.Cord blood neutrophils display a galectin-3 responsive phenotype accentuated by vaginal delivery.Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).Advances in tenascin-C biology.Effect of postconditioning on dynamic expression of tenascin-C and left ventricular remodeling after myocardial ischemia and reperfusion.Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation.Calciotropic and Phosphaturic Hormones in End-Stage Heart Failure Patients Supported by a Left-Ventricular Assist Device.Influence of Mechanical Circulatory Support on Endothelin Receptor Expression in Human Left Ventricular Myocardium from Patients with Dilated Cardiomyopathy (DCM).Serum Galectin-9 Levels Are Associated with Coronary Artery Disease in Chinese Individuals Galectin-3: a novel biomarker for the prognosis of heart failure.Serial galectin-3 and future cardiovascular disease in the general population.Galectin-3 in cardiac remodeling and heart failure.Novel biomarkers in human terminal heart failure and under mechanical circulatory support.Matricellular proteins: new molecular targets to prevent heart failure.Personalizing biomarker strategies in heart failure with galectin-3.Clinical utility of biomarkers in chronic kidney disease and chronic heart failure.The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers.The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure.Biomarkers in mechanical circulatory support.Heart failure and galectin 3.Prognostic value of galectin-3 in patients with heart failure.Interleukin 1 Receptor-Like 1 Protein (ST2) is a Potential Biomarker for Cardiomyopathy in Duchenne Muscular Dystrophy.Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure.Biomarkers to Predict Reverse Remodeling and Myocardial Recovery in Heart Failure.Using galectin-3 to reduce heart failure rehospitalization.The role of tenascin-C in tissue injury and tumorigenesis.Novel Heart Failure Biomarkers Predict Improvement of Mitral Regurgitation in Patients Receiving Cardiac Resynchronization Therapy-The BIOCRT Study.Value of pentraxin-3 and galectin-3 in acute coronary syndrome: a short-term prospective cohort study.Galectin-3 levels in patients with hypertrophic cardiomyopathy and its relationship with left ventricular mass index and function.Cellular, molecular, genomic changes occurring in the heart under mechanical circulatory support.Clinical trials update from the Heart Failure Society of America Meeting 2009: FAST, IMPROVE-HF, COACH galectin-3 substudy, HF-ACTION nuclear substudy, DAD-HF, and MARVEL-1.Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure.Global gene expression analysis in nonfailing and failing myocardium pre- and postpulsatile and nonpulsatile ventricular assist device support.

P2860

Q24651908-807E57BE-185A-4B6D-9DE3-B490F2AC3CD6 Q33529398-5493CAA9-9E9D-4E12-8C9B-7FAA03B6690F Q33577541-48A4BEBE-0D8B-441E-8EC9-98CC1A4F5964 Q33754895-6A26EFC5-2E2E-479A-88C2-702E0AEFF0AF Q33912126-6535984D-6DFF-47D4-82D7-908FEC6BECE6 Q33965302-AAAF9CFF-7F11-46B9-A891-32E21001E53C Q34032111-5A52F98B-AB0B-4199-BE2E-1B7DC357D116 Q34528187-9FD4B862-3B64-4ECE-9A97-B20CB6075AF9 Q34960351-47C1B5FD-9063-4C9D-96E6-D231D5F05F8B Q35206146-66A3852D-6C1C-41B9-B90B-531243AFC109 Q35214557-9C0C40EF-805B-415E-9902-43CBEBEEECFF Q35365832-D62C48D0-33BD-4A80-A11C-E49FFBE377D7 Q36052222-55ADEFC9-2679-4668-A4D3-0E1C08D3BB18 Q36176069-2196F883-0D5E-43E6-B34E-7E7934C8D6CC Q36251275-508607DB-7DE2-4EA3-B05A-887AE2AEE8F5 Q36339546-D771418E-8690-45C3-8B93-D864CCA4A256 Q36385583-BADBC01D-E3BC-4DB7-9B1D-FF65866A0A9A Q37580709-776252B7-9663-4711-AD5C-0170D3E0A1DF Q37738648-12C59B2E-E6B2-40A9-B018-F767F7693D70 Q37894731-6867C4A7-3C05-4ED4-A1B4-CFD028AB1C24 Q37925022-1EDDDB45-1630-41BC-B8FB-B6C4CCB1DCF7 Q38062031-35A04D89-BA91-4B19-BD18-287AAF9869CD Q38125509-A4EC12F4-654F-4A7F-B17F-56445DDEEBF6 Q38154222-0823D072-2846-49B7-ADE4-7B42CDFB02D9 Q38194209-F21AFB86-B472-4EBB-A939-CF0B73DF619B Q38249997-95C9FDCA-0E17-4EE9-B385-D1AD15290963 Q38269044-1792FA29-EEA8-4B53-961A-FD33BF276AB1 Q38471023-C5823573-E7D8-463C-A374-B29638C1963E Q38640186-E442F624-1F69-4E8C-9BE0-0732C745FAAC Q38687046-22F97020-5EC8-44EA-8572-399DF3B84CEE Q38977493-B906713D-F69F-4B92-8DF0-CC254F56F374 Q39204234-68BBE265-06B5-4993-8EE6-8D3CD51F2FB0 Q39280466-28635D9D-1328-480C-AAE9-D87AE1FDEE00 Q40621297-BC42F06B-2025-4680-B6B8-CF7CD8AD50AF Q41151739-1C0C5957-1AD6-45CE-8584-DDB842818176 Q42191449-5D9B4068-3FD5-4E81-B806-2FD8ECB59081 Q43002918-47EECD92-C3C8-4096-8EAF-97CCD8A69AAD Q43204655-5A10C57C-2660-48E1-8F28-6B01E8699403 Q44426645-5C26EF3A-B668-447E-8076-9AB708252F26 Q45153672-E147247F-5020-4765-9590-48F8EB0348BC

P2860

Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices.

http://www.wikidata.org/entity/Q47682346

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Plasma biomarkers of myocardia ...... l circulatory support devices.

@en

Plasma biomarkers of myocardia ...... l circulatory support devices.

@nl

type

label

Plasma biomarkers of myocardia ...... l circulatory support devices.

@en

Plasma biomarkers of myocardia ...... l circulatory support devices.

@nl

prefLabel

Plasma biomarkers of myocardia ...... l circulatory support devices.

@en

Plasma biomarkers of myocardia ...... l circulatory support devices.

@nl

P1433

Q47682346-1159E52E-91C5-490D-A1D1-4E4BEDCAD830

P1476

Q47682346-D3ED94A5-1C7D-4C63-92B8-394CCEB712A0

P2093

Q47682346-348508A5-3867-4A6E-8BC1-7443D500F61C

Q47682346-44883E4C-D80A-4C9A-94C8-C232ACC9CD33

Q47682346-4BF00E9E-DD9C-4262-B513-22A6913EBBE7

Q47682346-6AA4BB42-B257-45F4-A05D-82151E873B6E

Q47682346-6F3CA38B-B592-4F5A-ADC1-AB599ED2DB2A

Q47682346-735C3DE0-9577-41A0-A429-32929D19BF11

Q47682346-8A95BAF0-9550-4D16-BC90-D7AEEF7A100B

Q47682346-9F478BC3-1002-4E21-8B77-06FD4BFF91AA

Q47682346-D783649D-4545-4CF7-BEAB-F107ABEE71F4

Q47682346-E4567EE7-4343-4CDB-A86D-656A88C06491

P304

Q47682346-71FA28B6-67E3-4625-824E-9069C0159350

P31

Q47682346-6141E3CB-7E06-4C83-97BE-8536AC70F28A

P356

Q47682346-8A29E120-BD8B-4D22-9BDB-F6B1FCF8285D

P433

Q47682346-E26D7733-7551-41CD-9C6B-5B12A534BE50

P478

Q47682346-71F48FF9-D851-4D9F-A8CF-072A878A76FD

P577

Q47682346-4971D880-7961-44D4-BC03-4F091A637BF5

P698

Q47682346-88538822-826A-45F7-A230-6CD603316918

P921

Q47682346-D69D0181-BD31-41CF-B433-A4F0D0F3355D

Q47682346-DFCA7A2E-0B15-40A5-AFDF-AC179FDA5FB0

Q47682346-FC4FAAC4-7738-43BA-94A8-B763E9ADB11A

P356

J.HEALUN.2008.02.018

P1433

The Journal of Heart and Lung Transplantation

P1476

Plasma biomarkers of myocardia ...... l circulatory support devices.

@en

P2093

Aly El Banayosy

http://www.w3.org/2001/XMLSchema#string

Astrid Kassner

http://www.w3.org/2001/XMLSchema#string

Birte Bohms

http://www.w3.org/2001/XMLSchema#string

Frank Kramer

http://www.w3.org/2001/XMLSchema#string

Hamdin Cakar

http://www.w3.org/2001/XMLSchema#string

Hendrik Milting

http://www.w3.org/2001/XMLSchema#string

Lothar Kruska

http://www.w3.org/2001/XMLSchema#string

Martina Klein

http://www.w3.org/2001/XMLSchema#string

Michael Seewald

http://www.w3.org/2001/XMLSchema#string

Peter Ellinghaus

http://www.w3.org/2001/XMLSchema#string

P304

589-596

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.HEALUN.2008.02.018

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2008-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18503956

http://www.w3.org/2001/XMLSchema#string

P921